1.Splenic myeloid metaplasia in warm autoimmune hemolytic anemia (wAIHA): a retrospective study.
Víctor Manuel ANGUIANO-ÁLVAREZ ; Alonso HERNÁNDEZ-COMPANY ; Nashla HAMDAN-PÉREZ ; Daniel MONTANTE-M ; Diego A ZÚÑIGA-TAMAYO ; Sergio RODRÍGUEZ-RODRÍGUEZ ; Alan POMERANTZ ; Elena J TUNA-AGUILAR
Blood Research 2018;53(1):35-40
BACKGROUND: Splenic myeloid metaplasia (SMM) is a kind of extramedullary hematopoiesis, whereas its clinical significance in wAIHA remains unclear. The aim of this study is evaluating the frequency and clinical characteristics of SMM, compared with splenic-congestion (SC). METHODS: We included patients with wAIHA treated in a Mexican tertiary hospital between January 1992 and December 2015. All patients received steroids as first-line treatment and splenectomy as second-line treatment. RESULTS: Among the thirty-six splenectomized patients, 15 (41.6%) and 21 (58.4%) were diagnosed as SMM and SC, respectively. No differences were found in clinical characteristics between two groups. SMM patients showed lower platelet count (147×109/L vs. 240×109/L, P=0.02) and higher presence of anti-dsDNA antibodies (40% vs. 4.7%, P=0.01) than SC patients. Although the complete response (CR) rate with first-line treatment was lower in SMM patients (13.3% vs. 47.6%; P=0.04), post-splenectomy median disease-free-survival (DFS) was longer (16.2 mo vs. 5.1 mo; P=0.19). Univariate/multivariate analysis showed that achieving CR during first-line treatment (OR 0.3, 95% CI: 0.03–0.94, P=0.03) and higher platelet count (OR 0.99, 95% CI: 0.98–0.99, P=0.03) were protective factors for SMM; and anti-dsDNA titer higher than 9.6 IU/dL was a risk factor for SMM (OR 2.76, 95% CI: 1.48–5.14, P < 0.001). CONCLUSION: The wAIHA patients with SMM have different biological profiles with those without SMM. This study is the first trial evaluating the significance of histopathological spleen findings and their association with rheumatologic profile.
Anemia, Hemolytic, Autoimmune*
;
Antibodies
;
Hematopoiesis, Extramedullary
;
Humans
;
Platelet Count
;
Primary Myelofibrosis*
;
Protective Factors
;
Retrospective Studies*
;
Risk Factors
;
Spleen
;
Splenectomy
;
Steroids
;
Tertiary Care Centers
2.Effectiveness of Thrombectomy in Stroke According to Baseline Prognostic Factors: Inverse Probability of Treatment Weighting Analysis of a Population-Based Registry
Salvatore RUDILOSSO ; José RÍOS ; Alejandro RODRÍGUEZ ; Meritxell GOMIS ; Víctor VERA ; Manuel GÓMEZ-CHOCO ; Arturo RENÚ ; Núria MATOS ; Laura LLULL ; Francisco PURROY ; Sergio AMARO ; Mikel TERCEÑO ; Víctor OBACH ; Joaquim SERENA ; Joan MARTÍ-FÀBREGAS ; Pedro CARDONA ; Carlos MOLINA ; Ana RODRÍGUEZ-CAMPELLO ; David CÁNOVAS ; Jerzy KRUPINSKI ; Xavier USTRELL ; Ferran TORRES ; Luis San ROMÁN ; Mercè SALVAT-PLANA ; Francesc Xavier JIMÉNEZ-FÀBREGA ; Ernest PALOMERAS ; Esther CATENA ; Carla COLOM ; Dolores COCHO ; Juanjo BAIGES ; Josep Maria ARAGONES ; Gloria DIAZ ; Xavier COSTA ; María Cruz ALMENDROS ; Maria RYBYEBA ; Miquel BARCELÓ ; Dolors CARRIÓN ; Matilde Núria LÒPEZ ; Eduard SANJURJO ; Natalia Pérez DE LA OSSA ; Xabier URRA ; Ángel CHAMORRO ;
Journal of Stroke 2021;23(3):401-410
Background:
and Purpose In real-world practice, the benefit of mechanical thrombectomy (MT) is uncertain in stroke patients with very favorable or poor prognostic profiles at baseline. We studied the effectiveness of MT versus medical treatment stratifying by different baseline prognostic factors. Methods Retrospective analysis of 2,588 patients with an ischemic stroke due to large vessel occlusion nested in the population-based registry of stroke code activations in Catalonia from January 2017 to June 2019. The effect of MT on good functional outcome (modified Rankin Score ≤2) and survival at 3 months was studied using inverse probability of treatment weighting (IPTW) analysis in three pre-defined baseline prognostic groups: poor (if pre-stroke disability, age >85 years, National Institutes of Health Stroke Scale [NIHSS] >25, time from onset >6 hours, Alberta Stroke Program Early CT Score <6, proximal vertebrobasilar occlusion, supratherapeutic international normalized ratio >3), good (if NIHSS <6 or distal occlusion, in the absence of poor prognostic factors), or reference (not meeting other groups’ criteria).
Results:
Patients receiving MT (n=1,996, 77%) were younger, had less pre-stroke disability, and received systemic thrombolysis less frequently. These differences were balanced after the IPTW stratified by prognosis. MT was associated with good functional outcome in the reference (odds ratio [OR], 2.9; 95% confidence interval [CI], 2.0 to 4.4), and especially in the poor baseline prognostic stratum (OR, 3.9; 95% CI, 2.6 to 5.9), but not in the good prognostic stratum. MT was associated with survival only in the poor prognostic stratum (OR, 2.6; 95% CI, 2.0 to 3.3).
Conclusions
Despite their worse overall outcomes, the impact of thrombectomy over medical management was more substantial in patients with poorer baseline prognostic factors than patients with good prognostic factors.
3.Effectiveness of Thrombectomy in Stroke According to Baseline Prognostic Factors: Inverse Probability of Treatment Weighting Analysis of a Population-Based Registry
Salvatore RUDILOSSO ; José RÍOS ; Alejandro RODRÍGUEZ ; Meritxell GOMIS ; Víctor VERA ; Manuel GÓMEZ-CHOCO ; Arturo RENÚ ; Núria MATOS ; Laura LLULL ; Francisco PURROY ; Sergio AMARO ; Mikel TERCEÑO ; Víctor OBACH ; Joaquim SERENA ; Joan MARTÍ-FÀBREGAS ; Pedro CARDONA ; Carlos MOLINA ; Ana RODRÍGUEZ-CAMPELLO ; David CÁNOVAS ; Jerzy KRUPINSKI ; Xavier USTRELL ; Ferran TORRES ; Luis San ROMÁN ; Mercè SALVAT-PLANA ; Francesc Xavier JIMÉNEZ-FÀBREGA ; Ernest PALOMERAS ; Esther CATENA ; Carla COLOM ; Dolores COCHO ; Juanjo BAIGES ; Josep Maria ARAGONES ; Gloria DIAZ ; Xavier COSTA ; María Cruz ALMENDROS ; Maria RYBYEBA ; Miquel BARCELÓ ; Dolors CARRIÓN ; Matilde Núria LÒPEZ ; Eduard SANJURJO ; Natalia Pérez DE LA OSSA ; Xabier URRA ; Ángel CHAMORRO ;
Journal of Stroke 2021;23(3):401-410
Background:
and Purpose In real-world practice, the benefit of mechanical thrombectomy (MT) is uncertain in stroke patients with very favorable or poor prognostic profiles at baseline. We studied the effectiveness of MT versus medical treatment stratifying by different baseline prognostic factors. Methods Retrospective analysis of 2,588 patients with an ischemic stroke due to large vessel occlusion nested in the population-based registry of stroke code activations in Catalonia from January 2017 to June 2019. The effect of MT on good functional outcome (modified Rankin Score ≤2) and survival at 3 months was studied using inverse probability of treatment weighting (IPTW) analysis in three pre-defined baseline prognostic groups: poor (if pre-stroke disability, age >85 years, National Institutes of Health Stroke Scale [NIHSS] >25, time from onset >6 hours, Alberta Stroke Program Early CT Score <6, proximal vertebrobasilar occlusion, supratherapeutic international normalized ratio >3), good (if NIHSS <6 or distal occlusion, in the absence of poor prognostic factors), or reference (not meeting other groups’ criteria).
Results:
Patients receiving MT (n=1,996, 77%) were younger, had less pre-stroke disability, and received systemic thrombolysis less frequently. These differences were balanced after the IPTW stratified by prognosis. MT was associated with good functional outcome in the reference (odds ratio [OR], 2.9; 95% confidence interval [CI], 2.0 to 4.4), and especially in the poor baseline prognostic stratum (OR, 3.9; 95% CI, 2.6 to 5.9), but not in the good prognostic stratum. MT was associated with survival only in the poor prognostic stratum (OR, 2.6; 95% CI, 2.0 to 3.3).
Conclusions
Despite their worse overall outcomes, the impact of thrombectomy over medical management was more substantial in patients with poorer baseline prognostic factors than patients with good prognostic factors.